GlassScriptPhysician profile
Zhexiang S Li
NPI 1710929898
$4,953.44
in general payments reported to CMS, 2019-2025
35 companies · $758 in 2025
The $758 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $520 · 2021: $1,143 · 2022: $600 · 2023: $726 · 2024: $653 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $771.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $554.49 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $466.61 | 2021-2025 | |
| Astellas Pharma US INC | $416.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $361.97 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.90 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $239.82 | 2019-2021 | |
| Pfizer INC. | $238.17 | 2019-2025 | |
| Exact Sciences Corporation | $201.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $182.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $167.70 | 2023-2025 | Arexvy, Shingrix |
| Pharming Healthcare, INC. | $130.08 | 2024 | Ruconest |
| Corcept Therapeutics | $107.92 | 2023 | Korlym |
| Otsuka America Pharmaceutical, INC. | $94.70 | 2024-2025 | Rexulti |
| Abbott Laboratories | $81.95 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $74.73 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $55.49 | 2021 | |
| Amgen INC. | $53.22 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $48.45 | 2023-2025 | Contrave |
| Amarin Pharma, INC. | $42.67 | 2019 | |
| Biogen, INC. | $39.01 | 2021-2024 | Leqembi |
| Novartis Pharmaceuticals Corporation | $38.96 | 2021-2022 | |
| Mylan Specialty L.P. | $27.54 | 2019-2020 | |
| Ibsa Pharma INC. | $26.55 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.42 | 2022-2023 | Quviviq |
| Allergan, INC. | $25.21 | 2019-2020 | |
| Althera Pharmaceuticals LLC | $23.34 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $19.46 | 2025 | Imcivree |
| Sanofi Pasteur INC. | $15.22 | 2024 | |
| Eisai INC. | $14.90 | 2019 | |
| Acorda Therapeutics, INC | $14.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.73 | 2023 | Seglentis |
| Acadia Pharmaceuticals INC | $13.71 | 2019 | |
| Axsome Therapeutics, INC. | $12.89 | 2023 | Sunosi |
| Genentech USA, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhexiang Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.